^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Camrelizumab (SHR-1210) With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer: a Single-Arm, Phase II Study
Excerpt:
...Patients who need to obtain tumor tissue for EGFR mutation detection before operation, and no sensitive mutation was found in the EGFR detection results; 7. ...
Trial ID:
Source:
Title:
Neoadjuvant camrelizumab plus apatinib or camrelizumab plus apatinib and chemotherapy as anti PD-1 treatment for resectable II-IIIA non-small cell lung cancer
Excerpt:
...Without specific driven gene mutation like EGFR, ALK and so on; 5. ...
Trial ID:
More C2 evidence
Source:
Title:
Clinical study of Camrelizumab combined with Apatinib mesylate and chemotherapy in patients with advanced lung adenocarcinoma
Excerpt:
...Patients with negative EGFR, ALK and ros1 mutations; 6. ...
Trial ID:
Source:
Title:
A single-arm, exploratory clinical study of camrelizumab combined with apatinib mesylate and standard chemotherapy in the neoadjuvant treatment of stage IIIA non-small cell lung cancer
Excerpt:
...If the pathological diagnosis is adenocarcinoma, genetic testing is also required to confirm that there is no sensitive gene mutation (including but not limited to EGFR (18-21 locus), ALK mutation, etc.); 3. ...
Trial ID:
Source:
Title:
A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC
Excerpt:
...EGFR mutation and alk translocation status were confirmed to be negative at any time after the initial diagnosis; 4....
Trial ID:
Source:
Title:
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer
Excerpt:
...Patients who need to obtain tumor tissue for EGFR mutation detection before operation, and...
Trial ID:
Source:
Title:
A single-arm, prospective, open-label clinical study of carilizumab combined with apatinib in the treatment of non-small cell lung cancer with TP53 gene mutation
Excerpt:
...Patients with EGFR gene mutation or ALK gene rearrangement, who have received standard treatment to obtain disease progress and have TP53 gene mutation detected; 5. ...
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy of camrelizumab (SHR-1210) plus apatinib with or without stereotactic body radiotherapy (SBRT) as higher-line therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC).
Published date:
05/19/2021
Excerpt:
...NSCLC patients aged 18-75 years, with EGFR-sensitizing mutations, and progression after at least one kind of EGFR TKI were enrolled. All patients received intravenous camrelizumab (200 mg, D1) plus oral apatinib... ORR and disease control rate was 15% (2/13) and 62% (8/13), respectively....Camrelizumab plus apatinib with or without SBRT as higher-line therapy showed benefit to patients with EGFR-mutant NSCLC.
DOI:
10.1200/JCO.2021.39.15_suppl.e21128
Source:
Title:
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
Excerpt:
Previously treated patients with advanced EGFR+/ALK+ NSCLC were enrolled and given camrelizumab 200 mg intravenously every 2 weeks plus apatinib at the recommended dose of 250 mg orally once daily…. The confirmed ORR was 18.6% (95% CI: 8.4–33.4%) and the clinical benefit response rate was 27.9% (95% CI: 15.3–43.7%).
DOI:
10.21037/tlcr-22-22
Trial ID:
